SEC Form 4 · accession 0000899243-16-034428
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory Behar
Director
Period of report
Nov 23, 2016
Accepted (ET)
Nov 28, 2016 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $24.90 | Nov 23, 2016 | A | 39,510 | A | — | Nov 22, 2026 | Common Stock | 39,510 | 39,510 | D |
Explanation of responses
- F1The shares subject to the option will vest and become exercisable with respect to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from November 23, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.